Literature DB >> 22253527

Concurrent systemic AA amyloidosis can discriminate primary sclerosing cholangitis from IgG4-associated cholangitis.

Takehiro Kato1, Atsumasa Komori, Sung-Kwan Bae, Kiyoshi Migita, Masahiro Ito, Yasuhide Motoyoshi, Seigo Abiru, Hiromi Ishibashi.   

Abstract

Chronic hepatobiliary inflammatory diseases are not widely acknowledged as underlying disorders of systemic AA amyloidosis, except epidemic schistosomiasis. Among them, primary sclerosing cholangitis (PSC) might initiate amyloid A protein deposition in diverse tissues, giving rise to systemic amyloidosis, due to a progressive and unresolved inflammatory process, and its possible association with inflammatory bowel diseases. Nevertheless, only one such case has been reported in the literature to date. We report a 69-year-old Japanese woman with cirrhosis who was diagnosed with PSC complicated with systemic AA amyloidosis, without any evidence of other inflammatory disorders. As a result of cholestasis in conjunction with biliary strictures and increased serum IgG4, the presence of IgG4(+) plasma cells was examined systemically, resulting in unexpected documentation of Congo-red-positive amyloid deposits, but not IgG4(+) plasma cells, in the liver, stomach and salivary glands. Elevated serum IgG4 is the hallmark of IgG4-related disease, including IgG4-associated cholangitis, but it has also been demonstrated in certain patients with PSC. Amyloid A deposits in multiple organs associated with an indolent clinical course that progresses over many years might have a diagnostic value in discriminating PSC from IgG4-associated cholangitis.

Entities:  

Keywords:  AA amyloidosis; IgG4-associated cholangitis; Primary sclerosing cholangitis

Mesh:

Substances:

Year:  2012        PMID: 22253527      PMCID: PMC3257448          DOI: 10.3748/wjg.v18.i2.192

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  16 in total

1.  Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis.

Authors:  Yasuaki Okuda; Kiyoshi Takasugi
Journal:  Arthritis Rheum       Date:  2006-09

2.  Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study.

Authors:  Jens J W Tischendorf; Hartmut Hecker; Martin Krüger; Michael P Manns; Peter N Meier
Journal:  Am J Gastroenterol       Date:  2006-10-13       Impact factor: 10.864

Review 3.  Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature.

Authors:  Einar Björnsson; Suresh T Chari; Thomas C Smyrk; Keith Lindor
Journal:  Hepatology       Date:  2007-06       Impact factor: 17.425

4.  Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis.

Authors:  Flavia D Mendes; Roberta Jorgensen; Jill Keach; Jerry A Katzmann; Thomas Smyrk; Jessica Donlinger; Suresh Chari; Keith D Lindor
Journal:  Am J Gastroenterol       Date:  2006-07-27       Impact factor: 10.864

Review 5.  Recent advances in the concept and diagnosis of autoimmune pancreatitis and IgG4-related disease.

Authors:  Kazuichi Okazaki; Kazushige Uchida; Masanori Koyabu; Hideaki Miyoshi; Makoto Takaoka
Journal:  J Gastroenterol       Date:  2011-03-11       Impact factor: 7.527

6.  Serum IgG4 concentrations in pancreatic and biliary diseases.

Authors:  Kenji Hirano; Takao Kawabe; Natsuyo Yamamoto; Yousuke Nakai; Naoki Sasahira; Takeshi Tsujino; Nobuo Toda; Hiroyuki Isayama; Minoru Tada; Masao Omata
Journal:  Clin Chim Acta       Date:  2006-01-19       Impact factor: 3.786

7.  Serum amyloid A1 alleles and plasma concentrations of serum amyloid A.

Authors:  T Yamada; A Wada; Y Itoh; K Itoh
Journal:  Amyloid       Date:  1999-09       Impact factor: 7.141

8.  Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy.

Authors:  Amaar Ghazale; Suresh T Chari; Lizhi Zhang; Thomas C Smyrk; Naoki Takahashi; Michael J Levy; Mark D Topazian; Jonathan E Clain; Randall K Pearson; Bret T Petersen; Santhi Swaroop Vege; Keith Lindor; Michael B Farnell
Journal:  Gastroenterology       Date:  2007-12-07       Impact factor: 22.682

9.  Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations.

Authors:  H J Lachmann; B Sengül; T U Yavuzşen; D R Booth; S E Booth; A Bybee; J R Gallimore; M Soytürk; S Akar; M Tunca; P N Hawkins
Journal:  Rheumatology (Oxford)       Date:  2006-01-10       Impact factor: 7.580

10.  Natural history and outcome in systemic AA amyloidosis.

Authors:  Helen J Lachmann; Hugh J B Goodman; Janet A Gilbertson; J Ruth Gallimore; Caroline A Sabin; Julian D Gillmore; Philip N Hawkins
Journal:  N Engl J Med       Date:  2007-06-07       Impact factor: 91.245

View more
  3 in total

Review 1.  Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver.

Authors:  María Rojas-Feria; Manuel Castro; Emilio Suárez; Javier Ampuero; Manuel Romero-Gómez
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

Review 2.  Recent developments in the management of idiopathic cholestatic liver disease.

Authors:  Mohamad H Imam; Emma Weeding; Keith D Lindor
Journal:  Ann Gastroenterol       Date:  2012

Review 3.  Liver manifestations and complications in inflammatory bowel disease: A review.

Authors:  Rui Gaspar; Catarina Castelo Branco; Guilherme Macedo
Journal:  World J Hepatol       Date:  2021-12-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.